2MACE score predicts cardiovascular adverse events in real-world atrial fibrillation patients under rivaroxaban therapy. Data from EMIR study
Por:
Pastor, M, Marin, F, Anguita, M, Sanmartin, M, Rafols, C, Ynsaurriaga, F, Esquivas, G, Barrios, V, Sales, J, Pamias, R, Cabeza, A, Rodriguez, J and Goya, I
Publicada:
1 oct 2021
Categoría:
Cardiology and cardiovascular medicine
Resumen:
|